|
KMID : 0880420170180010042
|
|
Korean Journal of Radiology
2017 Volume.18 No. 1 p.42 ~ p.53
|
|
|
Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
|
|
Braschi Amirfarzan Marta
Tirumani Sree Harsha
Hodi Frank Stephen
Nishino Mizuki
|
|
|
Abstract
|
|
|
|
Over the past five years immune-checkpoint inhibitors have dramatically changed the therapeutic landscape of advanced solid and hematologic malignancies. The currently approved immune-checkpoint inhibitors include antibodies to cytotoxic T-lymphocyte antigen-4, programmed cell death (PD-1), and programmed cell death ligand (PD-L1 and PD-L2). Response to immune-checkpoint inhibitors is evaluated on imaging using the immune-related response criteria. Activation of immune system results in a unique toxicity profile termed immune-related adverse events. This article will review the molecular mechanism, clinical applications, imaging of immune-related response patterns and adverse events associated with immune-checkpoint inhibitors.
|
|
|
KEYWORD
|
|
|
Immune-checkpoint inhibitor, Toxicity, Response, Immune-related Response Criteria
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|